File Justin J. — SEC insider filings
SEC reporting owner CIK 1726277. 12 insider filings on record with FilingPulse; latest filed 2026-10-26.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2020-11-18 to 2026-10-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings — 72,854 shares, $57,094 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: purchase of 24,500 shares @ $1.03 ($25,235) in Evofem Biosciences, Inc., filed 2021-06-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Evofem Biosciences, Inc. (EVFM) | Chief Financial Officer | 7 | 3 legs · 72,854 sh · $57,094 | — | 6 |
| Lite Strategy, Inc. (LITS) | CEO, CFO and Secretary, Director | 5 | — | — | 5 |
Insider filings — File Justin J.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-26 | 4 | Lite Strategy, Inc. (LITS) | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2026-02-12 | 4 | Lite Strategy, Inc. (LITS) | Grant/award (A): 455,000 (derivative) | EDGAR |
| 2025-11-20 | 4/A | Lite Strategy, Inc. (LITS) | Grant/award (A): 180,000 (derivative) | EDGAR |
| 2025-11-18 | 4 | Lite Strategy, Inc. (LITS) | Grant/award (A): 635,000 (derivative) | EDGAR |
| 2025-07-17 | 4 | MEI Pharma, Inc. (MEIP) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-02-23 | 4 | Evofem Biosciences, Inc. (EVFM) | Grant/award (A): 450,000 @ $0 · Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2022-01-04 | 4 | Evofem Biosciences, Inc. (EVFM) | Disposition to issuer (D): 120,000 @ $0 | EDGAR |
| 2021-12-20 | 4 | Evofem Biosciences, Inc. (EVFM) | Purchase (P): 40,594 @ $0.37 | EDGAR |
| 2021-06-10 | 4 | Evofem Biosciences, Inc. (EVFM) | Purchase (P): 24,500 @ $1.03 | EDGAR |
| 2021-05-21 | 4 | Evofem Biosciences, Inc. (EVFM) | Tax withholding (F): 42,280 @ $0.86 | EDGAR |
| 2021-02-03 | 4 | Evofem Biosciences, Inc. (EVFM) | Grant/award (A): 200,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2020-11-18 | 4 | Evofem Biosciences, Inc. (EVFM) | Purchase (P): 7,760 @ $2.17 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-11-13 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1726277 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs